JW Life Science Corp

JW Life Science Corp maintains a relatively conservative capital structure, with a debt-to-equity ratio of 0.3, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.15, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's cash and equivalents are minimal at 108,290 KRW, and its net cash position is negative after subtracting total debt, signaling potential liquidity constraints.

Profitability metrics show that the company is generating a return on equity (ROE) of 3.27% and a return on assets (ROA) of 1.94%. These figures are below the typical thresholds for high-performing pharmaceutical firms, indicating that the company may not be utilizing its equity and assets as efficiently as its peers. The operating margin, calculated as operating income of 8,601,038,710 KRW on revenue of 55,334,236,250 KRW, is 15.55%, which is in line with the industry median for pharmaceutical firms.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification may expose the company to higher operational and market risks, particularly in the event of regulatory changes or market downturns in its primary operating region.

Looking ahead, the company's growth trajectory appears modest. Analysts have assigned a mean price target of 18,000 KRW, with a mean recommendation of 1.00 (strong buy), suggesting a positive outlook. However, the company's revenue growth is not explicitly detailed in the provided data, and the absence of a clear growth strategy or expansion plans in the narrative suggests that the company may be in a stable but not rapidly growing phase.

Risk factors for JW Life Science Corp include its medium liquidity risk, as highlighted by the negative net cash position after subtracting total debt. The company's dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. However, the company's capital expenditure of -1,574,413,030 KRW indicates a reduction in investment, which could signal a strategic shift or financial constraints.

Recent events, as reflected in the financial data, include a consistent operating cash flow of 8,738,735,440 KRW and a free cash flow of 7,470,934,370 KRW. These figures suggest that the company is generating sufficient cash to support its operations and potentially fund future growth initiatives. However, the lack of recent filings or transcripts limits the ability to assess the company's strategic direction and management commentary.

Analysts project 60.9% upside to a consensus target price of 18,000 KRW, signaling strong market confidence.

Cash conversion ratio of 1.7 outperforms the cohort median of 0.95, demonstrating efficient cash generation.

The company faces high credit risk, potentially impacting borrowing costs and financial flexibility in the near term.

Debt-to-equity ratio of 0.3 is below the cohort median, but high credit risk flags remain a concern.

Revenue KRW 64.33B, +17,4% YoY; Operating income −20,9% YoY.

• ▍Revenue KRW 64.33B, +17,4% YoY
• ▍Operating income −20,9% YoY
• ▍Net income −74,6% YoY
• ▍Free cash flow −72,5% YoY
• ▍Net margin 10.0%

Revenue KRW 62.61B, +8,0% YoY; Operating income −23,8% YoY.

• ▍Revenue KRW 62.61B, +8,0% YoY
• ▍Operating income −23,8% YoY
• ▍Net income −28,0% YoY
• ▍Free cash flow −34,6% YoY
• ▍Net margin 7.8%

Revenue KRW 62.26B, +14,5% YoY; Operating income +11,9% YoY.

• ▍Revenue KRW 62.26B, +14,5% YoY
• ▍Operating income +11,9% YoY
• ▍Net income +67,9% YoY
• ▍Free cash flow +59,2% YoY
• ▍Net margin 18.0%

Revenue KRW 68.63B, +24,0% YoY; Operating income +7,0% YoY.

• ▍Revenue KRW 68.63B, +24,0% YoY
• ▍Operating income +7,0% YoY
• ▍Net income +19,0% YoY
• ▍Free cash flow −5,9% YoY
• ▍Net margin 8.9%

Revenue KRW 54.79B; Operating income KRW 9.59B.

• ▍Revenue KRW 54.79B
• ▍Operating income KRW 9.59B
• ▍Net margin 46.4%

Revenue KRW 57.95B; Operating income KRW 9.29B.

• ▍Revenue KRW 57.95B
• ▍Operating income KRW 9.29B
• ▍Net margin 11.7%

Revenue KRW 54.40B; Operating income KRW 8.38B.

• ▍Revenue KRW 54.40B
• ▍Operating income KRW 8.38B
• ▍Net margin 12.2%

Revenue KRW 55.33B; Operating income KRW 8.60B.

• ▍Revenue KRW 55.33B
• ▍Operating income KRW 8.60B
• ▍Net margin 9.3%

Revenue KRW 257.83B, +15,9% YoY; Operating income −7,3% YoY.

• ▍Revenue KRW 257.83B, +15,9% YoY
• ▍Operating income −7,3% YoY
• ▍Net income −35,0% YoY
• ▍Free cash flow −38,7% YoY
• ▍Net margin 11.1%

Revenue KRW 222.48B, +7,5% YoY; Operating income +16,2% YoY.

• ▍Revenue KRW 222.48B, +7,5% YoY
• ▍Operating income +16,2% YoY
• ▍Net income +56,3% YoY
• ▍Free cash flow +51,0% YoY
• ▍Net margin 19.8%

Revenue KRW 206.86B, +9,5% YoY; Operating income +13,9% YoY.

• ▍Revenue KRW 206.86B, +9,5% YoY
• ▍Operating income +13,9% YoY
• ▍Net income +88,1% YoY
• ▍Free cash flow +99,5% YoY
• ▍Net margin 13.6%

Revenue KRW 188.93B, +11,3% YoY; Operating income −5,0% YoY.

• ▍Revenue KRW 188.93B, +11,3% YoY
• ▍Operating income −5,0% YoY
• ▍Net income +15,9% YoY
• ▍Free cash flow +1 275,9% YoY
• ▍Net margin 7.9%